Host Cell Protein and Other Bioresidual Impurities

The primary goal of this workstream is industry alignment on detection, identification, risk assessment and Host Cell Proteins (HCPs) control strategies. However, the team also shares best practice and knowledge on other types of impurities such as aggregates. The goals of the workstream have been and will be achieved through benchmarking and building a gap analysis of guidance to create a common understanding of agency requirements.

Control of problematic host cell proteins and other impurities in biological processes and products

Identifying and confirming all HCPs which are present in a manufacturing process and the end products is critical to ensure patient safety. Areas of concern include development of a robust manufacturing process, which effectively removes potentially problematic levels and types of HCPs. The workstream concentrates the majority of its efforts on problematic/abundant HCPs, as well as HCP control and attempts to keep abreast of associated ever changing Health authority requirements / concerns.

Other types of product and process related impurities can also present business, regulatory or patient safety risks. Whilst these tyoes of impurities are not considered to be as problematic to remove from a process or product, knowledge sharing and industry alignment is also necessary.

Reducing regulatory risk and risk to patient

The workstream focuses on several perspectives: regulatory, patient, product quality and financial. It also considers how a risk control strategy impacts the change process. To maintain assay integrity throughout the lifecycle, data depends on critical reagents. If internal rework is conducted, timelines can be impacted. It is important to mitigate all risk (regulatory, patient, timelines, resources, etc.) through shared understanding, and development of a harmonized approach (which could potentially lead to influencing regulators or meeting their expectations).

This workstream also enables sharing recommendations for assays and critical reagents, their management, maintenance and best practice in bridging studies. Regulatory and patient risk is reduced and risks in subsequent clinical trials can be avoided based on experience and knowledge.

Host Cell Protein and Other Bioresidual Impurities deliverables


Enzymatic activity assays – general usage assessment

2 November, 2022Member only

Characterization and risk assessment of host cell proteins using mass spectrometry

2 November, 2022Member only

Host cell protein risk assessment – Where we are with BioPhorum cross-company collaboration and what we have learnt from an industry perspective?

19 May, 2022Member only

“High-risk” host cell proteins (HCPs): A multi-company collaborative view

2 September, 2021Link

Host cell protein (HCP) : Benchmarking mass spectrometry standards for USP

11 March, 2019Member only

Host cell protein (HCP): Risk assessment tool and papers

25 June, 2018
1.32 MB

More related workstreams

Our workstreams focus on the areas with the greatest impact across the industry. Led by science, our members are problem-solving today’s sustainability issues. By working with the regulatory governance community, they are also creating future-ready outcomes for the industry.


Contact BioPhorum

To find out more about how BioPhorum can help your business, enter your details below and a member of our team will be in touch.

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.


BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.


Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Partner

Supply Partner is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.


Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Inaugural BioPhorum Quality face to face – get involved
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
Delivering a Cell and Gene Therapy Outbound Supply Chain Pathway for the Industry
DNA and Earth on blue background
A vision for the biopharmaceutical industry’s inbound supply chain
A major milestone – a harmonized approach to product carbon footprint data
Technology Roadmap V 2.0
BioPhorum Technology Roadmapping roadmap vision 2.0


Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.


Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.


BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.


A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Bioreactivity testing in single-use system biomanufacturing